Rachel M Squillace

Summary

Affiliation: ARIAD Pharmaceuticals
Country: USA

Publications

  1. pmc Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models
    Rachel M Squillace
    Department of Biology, ARIAD Pharmaceuticals Inc, Cambridge, MA, USA
    Int J Oncol 41:425-32. 2012
  2. doi Antitumor activity of ridaforolimus and potential cell-cycle determinants of sensitivity in sarcoma and endometrial cancer models
    Rachel M Squillace
    ARIAD Pharmaceuticals, Inc, 26 Landsdowne Street, Cambridge, MA 02139, USA
    Mol Cancer Ther 10:1959-68. 2011
  3. doi Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models
    Joseph M Gozgit
    ARIAD Pharmaceuticals, Inc, 26 Landsdowne Street, Cambridge, MA 02139, USA
    Cancer Chemother Pharmacol 71:1315-23. 2013
  4. doi Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens
    Victor M Rivera
    ARIAD Pharmaceuticals, Inc, 26 Landsdowne Street, Cambridge, MA 02139, USA
    Mol Cancer Ther 10:1059-71. 2011

Collaborators

Detail Information

Publications4

  1. pmc Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models
    Rachel M Squillace
    Department of Biology, ARIAD Pharmaceuticals Inc, Cambridge, MA, USA
    Int J Oncol 41:425-32. 2012
    ....
  2. doi Antitumor activity of ridaforolimus and potential cell-cycle determinants of sensitivity in sarcoma and endometrial cancer models
    Rachel M Squillace
    ARIAD Pharmaceuticals, Inc, 26 Landsdowne Street, Cambridge, MA 02139, USA
    Mol Cancer Ther 10:1959-68. 2011
    ..These results underscore the promise of ridaforolimus as a single agent or combination treatment of these tumor types and suggest novel potential predictive biomarkers of sensitivity to an mTOR inhibitor based on cell-cycle status...
  3. doi Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models
    Joseph M Gozgit
    ARIAD Pharmaceuticals, Inc, 26 Landsdowne Street, Cambridge, MA 02139, USA
    Cancer Chemother Pharmacol 71:1315-23. 2013
    ..The aim of this study was to examine the therapeutic potential of a rational drug combination based on the simultaneous targeting of mutant-FGFR2 and mTOR-driven signaling pathways in endometrial cancer cells...
  4. doi Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens
    Victor M Rivera
    ARIAD Pharmaceuticals, Inc, 26 Landsdowne Street, Cambridge, MA 02139, USA
    Mol Cancer Ther 10:1059-71. 2011
    ....